<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Gynecology/obstetrics</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Changchun Genescience Pharmaceuticals discloses new 17β-HSD1 inhibitors</title>
      <description>
        <![CDATA[Changchun Genescience Pharmaceuticals Co. Ltd. has prepared and tested new steroid compounds acting as estradiol 17-β-dehydrogenase 1 (HSD17B1; 17β-HSD1) inhibitors that are potentially useful for the treatment of endometriosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730068</guid>
      <pubDate>Wed, 01 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730068-changchun-genescience-pharmaceuticals-discloses-new-17-hsd1-inhibitors</link>
    </item>
    <item>
      <title>Insilico Medicine and Aska enter gynecological collaboration</title>
      <description>
        <![CDATA[Insilico Medicine Cayman Topco has established a strategic research collaboration with Aska Pharmaceutical Co. Ltd. to identify novel therapeutic targets for challenging gynecological conditions, including endometriosis, uterine fibroids and adenomyosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729879</guid>
      <pubDate>Wed, 25 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729879-insilico-medicine-and-aska-enter-gynecological-collaboration</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Gynecology-womens-health-female-reproductive-system.webp?t=1774455533" type="image/jpeg" medium="image" fileSize="650388">
        <media:title type="plain">Futuristic medical hologram illustration featuring the female reproductive system</media:title>
      </media:content>
    </item>
    <item>
      <title>Endocyclic’s ENDO-205 gains IND clearance for endometriosis</title>
      <description>
        <![CDATA[Endomet Biosciences Inc. (dba Endocyclic Therapeutics) has obtained IND clearance from the FDA for its lead program, ENDO-205, a first-in-class, nonhormonal targeted peptide therapeutic for endometriosis. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729860</guid>
      <pubDate>Tue, 24 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729860-endocyclics-endo-205-gains-ind-clearance-for-endometriosis</link>
    </item>
    <item>
      <title>Teijin Pharma and Aska partner in gynecological diseases</title>
      <description>
        <![CDATA[Teijin Pharma Ltd. has entered into a joint research agreement with Aska Pharmaceutical Co. Ltd. to jointly develop novel small-molecule drug candidates for gynecological diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728899</guid>
      <pubDate>Tue, 17 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728899-teijin-pharma-and-aska-partner-in-gynecological-diseases</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Sexual-health/womens-health-reproduction-ovaries-uterus-cervix.webp?t=1721747295" type="image/jpeg" medium="image" fileSize="118515">
        <media:title type="plain">Illustration of women's reproductive organs</media:title>
      </media:content>
    </item>
    <item>
      <title>Laborie acquires Jada from Organon in $465M deal</title>
      <description>
        <![CDATA[Laborie Medical Technologies Corp. secured a new gem for its maternal health with the acquisition of the Jada system from Organon & Co. The terms of the deal, first announced in November, included payment of $440 million at closing, with an additional $25 million tied to 2026 revenue targets.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728284</guid>
      <pubDate>Fri, 30 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728284-laborie-acquires-jada-from-organon-in-465m-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/04-01-Organon-Alydia-Jada.webp?t=1769799622" type="image/png" medium="image" fileSize="496662">
        <media:title type="plain">Jada device image</media:title>
        <media:description type="plain">Jada system for treatment of postpartum hemorrhage. Credit: Alydia Health</media:description>
      </media:content>
    </item>
    <item>
      <title>AI identifies pregnancies at risk of spontaneous pre-term birth</title>
      <author>greg.kaplan@clarivate.com</author>
      <description>
        <![CDATA[Prenaital ApS    has filed a patent for technology that may identify risks of spontaneous pre-term birth. Spontaneous preterm birth (sPTB) is usually defined as birth occurring before 37 weeks of gestation.&nbsp;<span style=" font-style: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; widows: 2; word-spacing: 0px; display: inline !important; float: none;">The invention relates to a method for predicting potential preterm birth from medical scan data, which may be used in practice by medical professionals for risk analysis and prognosis of potential pathologies.</span>
]]>
      </description>
      <guid>http://www.bioworld.com/articles/728085</guid>
      <pubDate>Fri, 23 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728085-ai-identifies-pregnancies-at-risk-of-spontaneous-pre-term-birth</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2026/Prenaital-23jan26.webp?t=1769194680" type="image/jpeg" medium="image" fileSize="160383">
        <media:title type="plain">Prenaital CEO and co-founders</media:title>
        <media:description type="plain">From left: Prenaital CEO and co-founder Tanja Danner, DTU professor and co-founder Aasa Feragen and Martin G. Tolsgaard, co-founder and senior physician at Rigshospitalet. Credit: Courtesy DTU. </media:description>
      </media:content>
    </item>
    <item>
      <title>Genedx delivers WGS prenatal testing</title>
      <description>
        <![CDATA[Genedx Holding Corp. launched Genomedx Prenatal, its whole genome sequencing test, to provide more definitive diagnoses of the causes of fetal abnormalities identified by ultrasound. By combining the company’s decade of experience in prenatal exome testing and its massive Genedx Infinity rare disease dataset, the test can determine not just whether a pregnancy has a risk of a genetic disorder but whether the fetus actually has a genetic disorder.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727585</guid>
      <pubDate>Wed, 07 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727585-genedx-delivers-wgs-prenatal-testing</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/GeneDx-Joe-Devaney-hero.webp?t=1767823478" type="image/jpeg" medium="image" fileSize="543413">
        <media:title type="plain">Genedx’s Director of Laboratory Innovation Joe Devaney</media:title>
        <media:description type="plain">Genedx’s director of laboratory innovation Joe Devaney. Credit: Genedx
</media:description>
      </media:content>
    </item>
    <item>
      <title>Surgical robotic maker Shenzhen Edge announces $154M HKEX IPO</title>
      <description>
        <![CDATA[Surgical robotics maker Shenzhen Edge Medical Co. Ltd. reported its initial public offering on the Hong Kong Stock Exchange to raise HKD$1.19 billion (US$154 million) to advance its pipeline of surgical robotic systems and expand its geographic footprint to markets outside China.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727307</guid>
      <pubDate>Wed, 31 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727307-surgical-robotic-maker-shenzhen-edge-announces-154m-hkex-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Shenzhen-Edge-Medical-Co.-Ltd.-Multi-Port-Endoscopic-Surgical-Robot-12-31.webp?t=1767210534" type="image/jpeg" medium="image" fileSize="208812">
        <media:title type="plain">Shenzhen Edge Medical Co. Ltd.’s Multi-Port Endoscopic Surgical Robot</media:title>
        <media:description type="plain">Shenzhen Edge Medical Co. Ltd.’s Multi-Port Endoscopic Surgical Robot</media:description>
      </media:content>
    </item>
    <item>
      <title>Bayosthiti AI to build India-specific RNA sequencing ecosystem</title>
      <description>
        <![CDATA[Bayosthiti AI Pvt Ltd. aims to make RNA sequencing and AI-based preventive health care affordable and accessible for the Indian market, leveraging intellectual property from its parent company, Biostate AI Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727660</guid>
      <pubDate>Wed, 31 Dec 2025 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727660-bayosthiti-ai-to-build-india-specific-rna-sequencing-ecosystem</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/thumb/India-digital-map.webp?t=1632951244" type="image/png" medium="image" fileSize="470231">
        <media:title type="plain">India map on technology concept background</media:title>
      </media:content>
    </item>
    <item>
      <title>Laparoscopic instruments maker Livsmed tops 2025 Kosdaq IPOs</title>
      <description>
        <![CDATA[Livsmed Inc. closed the year’s biggest Kosdaq IPO with a ₩135.85 billion (US$94 million) haul Dec. 24. Livsmed specializes in the development of hand-held multi-joint laparoscopic surgical instruments for minimally invasive procedures.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727284</guid>
      <pubDate>Mon, 29 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727284-laparoscopic-instruments-maker-livsmed-tops-2025-kosdaq-ipos</link>
      <media:content url="https://www.bioworld.com/ext/resources/2025/Livsmed-Artisential-29dec25.webp?t=1767041135" type="image/jpeg" medium="image" fileSize="36469">
        <media:title type="plain">Livsmed Artisential</media:title>
        <media:description type="plain">Livsmed Artisential laparoscopic instrument. Credit: Livsmed</media:description>
      </media:content>
    </item>
    <item>
      <title>Bayosthiti AI to build India-specific RNA sequencing ecosystem</title>
      <description>
        <![CDATA[Bayosthiti AI Pvt Ltd. aims to make RNA sequencing and AI-based preventive health care affordable and accessible for the Indian market, leveraging intellectual property from its parent company, Biostate AI Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727213</guid>
      <pubDate>Tue, 23 Dec 2025 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727213-bayosthiti-ai-to-build-india-specific-rna-sequencing-ecosystem</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/thumb/India-digital-map.webp?t=1632951244" type="image/png" medium="image" fileSize="470231">
        <media:title type="plain">India map on technology concept background</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s Cornerstone Robotics raises $200M series D round</title>
      <description>
        <![CDATA[Cornerstone Robotics Ltd. raised an oversubscribed $200 million series D round to accelerate commercialization of its flagship product, the Sentire Endoscopic Surgical System.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725991</guid>
      <pubDate>Fri, 14 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725991-chinas-cornerstone-robotics-raises-200m-series-d-round</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Cornerstone-Robotics-Sentire-Surgical-System-12nov25.webp?t=1763154095" type="image/jpeg" medium="image" fileSize="147992">
        <media:title type="plain">Cornerstone Robotics Sentire Surgical System</media:title>
        <media:description type="plain">Cornerstone Robotics Sentire Surgical System. Credit: Cornerstone Robotics Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Cyclana Bio raises funding to advance approach to endometriosis</title>
      <description>
        <![CDATA[Cyclana Bio Ltd. has closed a £5 million (US$6.7 million) pre-seed funding round.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725282</guid>
      <pubDate>Mon, 20 Oct 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725282-cyclana-bio-raises-funding-to-advance-approach-to-endometriosis</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Endometriosis.webp?t=1705616846" type="image/jpeg" medium="image" fileSize="146730">
        <media:title type="plain">Endometriosis</media:title>
        <media:description type="plain">In endometriosis, endometrial tissue, which typically only lines the uterus, migrates to other organs.</media:description>
      </media:content>
    </item>
    <item>
      <title>Fertilizable egg-like cells generated with DNA from skin cells</title>
      <description>
        <![CDATA[Generating gametes from nonreproductive tissues could help overcome infertility. Previous studies have successfully transformed stem cells into viable oocytes through cellular reprogramming. Scientists at Oregon Health & Science University (OHSU) developed a method to derive them from skin cells via somatic cell nuclear transfer (SCNT), unlocking a mechanism that blends mitosis and meiosis. Now, the researchers have taken another step forward by generating fertilizable eggs from human skin cells.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724671</guid>
      <pubDate>Wed, 01 Oct 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724671-fertilizable-egg-like-cells-generated-with-dna-from-skin-cells</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/Mitalipov-SCNT-oocyte-spindle-HERO.webp?t=1759331066" type="image/jpeg" medium="image" fileSize="601761">
        <media:title type="plain">Human SCNT oocyte with visible spindle before fertilization.</media:title>
        <media:description type="plain">Human SCNT oocyte with visible spindle (bright spot inside) before fertilization. Credit: Mitalipov laboratory, Oregon Health &amp;amp; Science University.</media:description>
      </media:content>
    </item>
    <item>
      <title>Pacbio’s Puretarget simplifies carrier screening</title>
      <description>
        <![CDATA[Up to 71% of people carry at least one pathogenic variant that could contribute to development of a heritable disorder in offspring, but until now, prospective parents often had to undergo multiple tests to understand their risks. Pacific Biosciences of California Inc. (Pacbio)’s expanded Puretarget portfolio provides a quicker and more streamlined solution as it covers all challenging tier 3 genes identified in the American College of Medical Genetics technical standard.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724458</guid>
      <pubDate>Mon, 29 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724458-pacbios-puretarget-simplifies-carrier-screening</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/pacbio_revio_sequencing_plate-29sept25.webp?t=1759182980" type="image/jpeg" medium="image" fileSize="400158">
        <media:title type="plain">Pacbio Revio sequencing plate</media:title>
        <media:description type="plain">Pacbio’s Revio system can process 100,000 samples per year to identify rare diseases. Credit: Pacific Biosciences of California Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Genescience Pharmaceuticals divulges new 17β-HSD1 inhibitors</title>
      <description>
        <![CDATA[Genescience Pharmaceuticals Co. Ltd. has synthesized sterols acting as estradiol 17-β-dehydrogenase 1 (HSD17B1; 17β-HSD1) inhibitors reported to be useful for the treatment of endometriosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724603</guid>
      <pubDate>Mon, 29 Sep 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724603-genescience-pharmaceuticals-divulges-new-17-hsd1-inhibitors</link>
    </item>
    <item>
      <title>Cellect develops menstrual products for cervical cancer screening</title>
      <description>
        <![CDATA[In what represents the first filing to have emerged in the name of Cellect Laboratories Inc., one of the start-up’s co-founders, Claire Theresa Murphy, describes their development of a non-invasive screening method that could one day replace the Pap test.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724230</guid>
      <pubDate>Wed, 24 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724230-cellect-develops-menstrual-products-for-cervical-cancer-screening</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/cellect-cervical-screening-25sept25.webp?t=1758745667" type="image/jpeg" medium="image" fileSize="72576">
        <media:title type="plain">Cellect cervical screening</media:title>
        <media:description type="plain">US20250288285-A1, “Functionalized nanomaterial for medical analyte collection”Assignee: Cellect Laboratories Inc.Inventors: Murphy, Claire Theresa; Klassen, Brandon William; Hung, Minren; Prophet, Lauren SarahIPC codes: A61B 5/15; A61B 5/00; A61F 13/20; A61B 10/02; A61F 13/47; A61F 13/472; A61F 13/512Publication date: Sep. 18, 2025Earliest priority details: US2024566776, March 18, 2024</media:description>
      </media:content>
    </item>
    <item>
      <title>Endocyclic’s ENDO-205 awarded NIH grant for endometriosis</title>
      <description>
        <![CDATA[Endocyclic Therapeutics (Endomet Biosciences Inc.) has been awarded a National Institute of Health (NIH) Commercialization Readiness Pilot (CRP) Program grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to accelerate the commercialization of ENDO-205, a nonhormonal, disease-modifying therapeutic designed to treat endometriosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724279</guid>
      <pubDate>Wed, 17 Sep 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724279-endocyclics-endo-205-awarded-nih-grant-for-endometriosis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Sexual-health/Gynecology-Endometriosis.webp?t=1677686044" type="image/png" medium="image" fileSize="538269">
        <media:title type="plain">Illustration of ovaries and uterus with endometriosis</media:title>
      </media:content>
    </item>
    <item>
      <title>Storx sensors monitor fetal health during labor and delivery</title>
      <description>
        <![CDATA[Researchers from the University of California, Davis (UC-Davis) continue to assemble intellectual property in support of their development of methods and techniques which improve the accuracy of wearable sensor technologies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723457</guid>
      <pubDate>Fri, 29 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723457-storx-sensors-monitor-fetal-health-during-labor-and-delivery</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/storx-sensors-29aug25.webp?t=1756498849" type="image/jpeg" medium="image" fileSize="242434">
        <media:title type="plain">Storx Sensors</media:title>
        <media:description type="plain">WO2025171056-A1, “Deep harmonic finesse: signal separation in wearable systems with limited data.”Assignee: The Regents of The University of California}Inventors: Ghiasi, Soheil; Saffarpour, MahyaIPC codes: G06F 18/2134; A61B 5/00; G06N 3/02Publication date: Aug. 14, 2025Earliest priority details: US2024550021, Feb. 24, 2024</media:description>
      </media:content>
    </item>
    <item>
      <title>Humanwell Healthcare identifies new angiotensin AT2 receptor antagonists</title>
      <description>
        <![CDATA[Humanwell Healthcare (Group) Co. Ltd. has described fused ring compounds acting as angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of disorders of the ovary and female reproductive tract, metabolic diseases, cardiovascular, eye, gastrointestinal, neurological, renal and respiratory disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722630</guid>
      <pubDate>Tue, 29 Jul 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722630-humanwell-healthcare-identifies-new-angiotensin-at2-receptor-antagonists</link>
    </item>
    <item>
      <title>CRVBC: Cardiac diseases can start in utero after immune migration</title>
      <description>
        <![CDATA[A healthy life for a healthy heart is a popular saying. However, even when following good habits, heart health can be already compromised from the very earliest stages of development. Maternal cells reach the embryo through the placenta contributing to its normal formation. So, just as the mother helps form a functional heart, she can also induce a condition that may not appear until adulthood.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721717</guid>
      <pubDate>Wed, 02 Jul 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721717-crvbc-cardiac-diseases-can-start-in-utero-after-immune-migration</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Human-embryo-7-weeks.webp?t=1751469926" type="image/jpeg" medium="image" fileSize="487384">
        <media:title type="plain">Illustration of anatomy of a human embryo at 7 weeks</media:title>
      </media:content>
    </item>
    <item>
      <title>UK Women to be offered home-testing kits for cervical screening</title>
      <description>
        <![CDATA[The U.K. government will offer women home-testing kits for cervical screening as part of an effort to tackle barriers and get more of them taking this potentially life-saving test.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721217</guid>
      <pubDate>Tue, 24 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721217-uk-women-to-be-offered-home-testing-kits-for-cervical-screening</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cervical-cancer-cell.webp?t=1719600239" type="image/png" medium="image" fileSize="316367">
        <media:title type="plain">Cervical cancer cell</media:title>
        <media:description type="plain">Cervical cancer cell.</media:description>
      </media:content>
    </item>
    <item>
      <title>AID system improves glycemic control in pregnancy</title>
      <description>
        <![CDATA[Pregnant women with type 1 diabetes who used a hybrid closed loop automated insulin delivery system averaged more than three additional hours per day in their recommended glucose range than those who managed their diabetes with insulin injections or non-automated pump systems, a study presented at the 85th Scientific Sessions of the American Association in Chicago demonstrated.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721215</guid>
      <pubDate>Tue, 24 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721215-aid-system-improves-glycemic-control-in-pregnancy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Sexual-health/Pregnancy.webp?t=1608060195" type="image/png" medium="image" fileSize="541206">
        <media:title type="plain">Pregnancy</media:title>
      </media:content>
    </item>
    <item>
      <title>Deepecho secures FDA clearance for fetal imaging platform</title>
      <description>
        <![CDATA[Deepecho Inc. received the U.S. FDA’s nod for its AI-based platform that assesses fetal biometry and amniotic fluid volume  to improve the efficiency and precision of fetal ultrasound diagnostics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721206</guid>
      <pubDate>Mon, 23 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721206-deepecho-secures-fda-clearance-for-fetal-imaging-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Digital-health-DNA-gene-therapy-research.webp?t=1686951391" type="image/jpeg" medium="image" fileSize="229766">
        <media:title type="plain">Art concept for gene therapy research</media:title>
      </media:content>
    </item>
    <item>
      <title>A human heart developed in a pig embryo over 21 days</title>
      <description>
        <![CDATA[Chinese researchers are preparing the details for the publication of another scientific milestone, the creation of a chimera with a human heart and a kidney developed from human stem cells in pig embryos.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721458</guid>
      <pubDate>Wed, 18 Jun 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721458-a-human-heart-developed-in-a-pig-embryo-over-21-days</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Ernst-Haeckel-embryonic-development-hero.webp?t=1750170554" type="image/jpeg" medium="image" fileSize="898639">
        <media:title type="plain">Ernst Haeckel's 1874 drawings of embryonic development. </media:title>
        <media:description type="plain">Ernst Haeckel's 1874 scientific drawings comparing embryonic development in fish, salamander, tortoise, bird, hog, calf, rabbit and man. Licensed under Creative Commons 4.0 from The Wellcome Collection.</media:description>
      </media:content>
    </item>
    <item>
      <title>A human heart developed in a pig embryo over 21 days</title>
      <description>
        <![CDATA[Chinese researchers are preparing the details for the publication of another scientific milestone, the creation of a chimera with a human heart and a kidney developed from human stem cells in pig embryos. These studies aim to address the shortage of immunocompatible organ donors while shedding light on some of the most fundamental questions in developmental biology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721289</guid>
      <pubDate>Tue, 17 Jun 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721289-a-human-heart-developed-in-a-pig-embryo-over-21-days</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Ernst-Haeckel-embryonic-development-hero.webp?t=1750170554" type="image/jpeg" medium="image" fileSize="898639">
        <media:title type="plain">Ernst Haeckel's 1874 drawings of embryonic development. </media:title>
        <media:description type="plain">Ernst Haeckel's 1874 scientific drawings comparing embryonic development in fish, salamander, tortoise, bird, hog, calf, rabbit and man. Licensed under Creative Commons 4.0 from The Wellcome Collection.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA’s device center playing guidance catch-up</title>
      <description>
        <![CDATA[The U.S. FDA’s Center for Devices and Radiological Health is recovering from a guidance drought that spanned several months in the first part of calendar year 2025, starting with a guidance on the Q-sub process.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720657</guid>
      <pubDate>Thu, 05 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720657-fdas-device-center-playing-guidance-catch-up</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Laptop-displaying-FDA-logo.webp?t=1695241730" type="image/png" medium="image" fileSize="347445">
        <media:title type="plain">Laptop displaying FDA logo</media:title>
      </media:content>
    </item>
    <item>
      <title>Mirvie offers preeclampsia risk prediction in US</title>
      <description>
        <![CDATA[Mirvie Inc. continues the development of precision medicine for pregnancy-related conditions with its Encompass blood test to predict preeclampsia risk and individualized support to head off the life-threatening complication that affects one in 12 pregnancies. The test, which received U.S. FDA breakthrough device designation in 2022, is now available to order online with clinician review via telehealth.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719926</guid>
      <pubDate>Wed, 14 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719926-mirvie-offers-preeclampsia-risk-prediction-in-us</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/Roh-Fig19.webp?t=1747260082" type="image/jpeg" medium="image" fileSize="62836">
        <media:title type="plain">Figure comparing normal pregnancy to peripartum cardiomyopathy preeclampsia</media:title>
      </media:content>
    </item>
    <item>
      <title>Germline variants’ impact on pan-cancer proteome</title>
      <description>
        <![CDATA[A large-scale study has revealed the impact of germline variants on proteins in 10 cancer types. Scientists from the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) conducted a precision proteogenomic analysis in a pan-cancer study with data from 1,064 patients, identifying tumor heterogeneity and tumorigenesis associated with heritable genetic alterations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719726</guid>
      <pubDate>Fri, 25 Apr 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719726-germline-variants-impact-on-pan-cancer-proteome</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Biology-cell-division-illustration.webp?t=1745335410" type="image/jpeg" medium="image" fileSize="344793">
        <media:title type="plain">Illustration of cell dividing</media:title>
      </media:content>
    </item>
    <item>
      <title>Germline variants’ impact on pan-cancer proteome</title>
      <description>
        <![CDATA[A large-scale study has revealed the impact of germline variants on proteins in 10 cancer types. Scientists from the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) conducted a precision proteogenomic analysis in a pan-cancer study with data from 1,064 patients, identifying tumor heterogeneity and tumorigenesis associated with heritable genetic alterations. The results provide a broad view of cancer risk that could be useful for patient stratification and the design of prevention strategies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719433</guid>
      <pubDate>Tue, 22 Apr 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719433-germline-variants-impact-on-pan-cancer-proteome</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Biology-cell-division-illustration.webp?t=1745335410" type="image/jpeg" medium="image" fileSize="344793">
        <media:title type="plain">Illustration of cell dividing</media:title>
      </media:content>
    </item>
  </channel>
</rss>
